NON-APPLICATION OF THE TENANT PROTECTION LAWS. 3.3.1 On the date of entry into force of the Protection of the Tenant [Consolidated Version] Law 5732 – 1972 the Lessee was not entitled to occupy the Object of the Lease. 3.3.2 The Lessee hereby declares that it has not been required to pay and has not paid any key money or any payments which are liable to be interpreted as key money and that all the works, changes, refurbishments and improvements which shall be made in the Object of the Lease, if any are made, are not and shall not be basic changes and also that the provisions of Part C of the Protection of the Tenant [Consolidated Version] Law 5732 – 1972 which deals with key money, shall not apply to the Lease. 3.3.3 The tenancy, the Lessee, and the Object of the Lease are not protected pursuant to the provisions of the Protection of the Tenant [Consolidated Version] Law 5732 – 1972 nor pursuant to the provisions of any other law which protects a lessee or tenant in any manner whatsoever, and the aforesaid laws and amendments thereto and the regulations which have been enacted or which may be enacted thereunder do not apply and also shall not apply to the building and/or the tenancy and/or the Lessee and/or the Object of the Lease and/or the Lease. 3.3.4 When the Object of the Lease is vacated the Lessee shall not be entitled to any payment whatsoever, neither as key money nor in any other manner whatsoever. 3.3.5 For the avoidance of doubt the Lessee hereby declares and undertakes that if any claims whatsoever are made in the future to the effect that the contractual relationship hereunder is protected pursuant to the Protection of the Tenant Law or any other law whatsoever, then the Lessee shall compensate the Lessor in respect of any damage it may incur, including the difference between the value of the Object of the Lease upon expiry of the Term of the Tenancy when occupied and the value thereof on the open market with vacant possession.
Appears in 2 contracts
Sources: Lease Agreement, Lease Agreement (Protalix BioTherapeutics, Inc.)